Bugs As Drugs: The Budding Microbiome Modulator Pipeline
Executive Summary
INFOGRAPHIC: The sheer number of micro-organisms in the human body and their functions makes the microbiome a ripe target for therapeutic intervention. While still rather early, data show the microbiome modulator pipeline has immense potential across a range of therapeutic areas, not just in gastrointestinal disease.
You may also be interested in...
AOBiome Targets Atopic Dermatitis Niche With Bacteria-Based Drug
While the atopic dermatitis market overall is crowded, the company sees a market opportunity for a drug that addresses both appearance and itching, as well as having favorable safety and ease of use.
‘Bugs As Drugs’ Approach To Cancer Nears Advanced Development
Microbiome modulators, known mainly for development in infectious and gastrointestinal diseases, could prove an asset in oncology thanks to the work of biotechs.
Double Blow For Sangamo’s Zinc Finger Approach As Novartis And Biogen Deals Collapse
The US biotech is facing yet another setback on its journey to proof-of-concept for its proprietary gene editing technology as two pharma firms back out of collaborations in the neurological space.